Influence of alpha-glutamil-tryptophan on the background and induced activity of factors of adaptive immunity for prevention

Background. During the ongoing COVID-19 pandemic and in the season of rising incidence of other respiratory infections, it is relevant to use preventive measures of  non-specific prophylaxis. Synthetic peptides are widely considered as a tool. The representative of this group is the synthetic analogue of thymus regulatory peptides Thymogen, which has been used in Russia for more than 20 years in the treatment of acute and chronic infection diseases.

The aim of the study. To evaluate the effect of Thymogen, a dosed nasal spray, on induced parameters of the immune system during prophylactic use in healthy volunteers.

Materials and methods. Twenty healthy volunteers received Thymogen nasal dosed spray (JSC  “Cytomed”, Russia) at a dose of 25  μg twice a day for 10  days. A  comparative assessment of  immunological parameters was carried out in dynamics: before the start of therapy, on days 6 and 11 of taking the drug and 14 days after the end of the course. Clinical observation was carried out from day 1 to day 11, registration of adverse events – the entire period of the study for 24 days. The first day was considered the day the drug was started.

Results. In the course of the work, according to the data of immunological examination, a statistically significant increase in the virus-induced production of interferon alpha (INF-α) by a culture of peripheral blood cells was revealed. The growth rate was recorded on day  11 of taking Thymogen and persisted for 14  days after  the  end  of  the  course. Significant differences in the dynamics of bactericidal and phagocytic activity of neutrophils, serum α- and γ-interferon were not obtained.

Conclusion. The use of Thymogen spray at a dose of 25 μg for 10 days was safe and contributed to a significant induction of interferon-alpha in response to exposure to a viral pathogen, which allows us to recommend the drug for prophylactic use during the period of rising incidence of acute respiratory diseases.

1. Biron CA. Innate immunity. In: Katze MG, Korth MJ, Law GL, Nathenson N (eds). Viral pathogenesis – From basics to systems biology. London: Academic Press; 2016: 41-55.

2. Bourdon M, Manet K, Montagutelli X. Host genetic susceptibility to viral infections: The role of type I interferon induction. Genes Immun. 2020; 21: 365-379. doi: 10.1038/s41435-020-00116-2

3. Sun L, Wang X, Saredy J, Yuan Z, Yang X, Wang H. Innate-adaptive immunity interplay and redox regulation in immune response. Redox Biol. 2020; 37: 101759. doi: 10.1016/j.redox.2020.101759

4. Rungelrath V, Kobayashi SD, DeLeo FR. Neutrophils in innate immunity and systems biology-level approaches. Wiley Interdiscip Rev Syst Biol Med. 2020; 12(1): e1458. doi: 10.1002/wsbm.1458

5. Chen Y, Lu D, Churov A, Fu R. Research progress on NK cell receptors and their signaling pathways. Mediators Inflamm. 2020; 2020: 6437057. doi: 10.1155/2020/6437057

6. Bojang E, Ghuman H, Kumwenda P, Hall RA. Immune sensing of Candida albicans. J Fungi (Basel). 2021; 7(2): 119. doi: 10.3390/jof7020119

7. Huang Y, Huaiu D, Ke R. Principles of effective and robust innate immune response to viral infections: A multiplex network analysis. Front Immunol. 2019; 10: 1736. doi: 10.3389/fimmu.2019.01736

8. Silin DS, Lyubomska OV, Ershov FI, Frolov VM, Kutsyna GA. Synthetic and natural immunomodulators acting as interferon inducers. Curr Pharmaceut Design. 2009; 15(11): 1238-1247. doi: 10.2174/138161209787846847

9. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol. 2012; 12: 125-135. doi: 10.1038/nri3133

10. Chiale C, Greene TT, Zuniga EI. Interferon induction, evasion, and paradoxical roles during SARS-CoV-2 I. Immunol Rev. 2022; 309(1): 12-24. doi: 10.1111/imr.13113

11. Made CI, Simons A, Schuurs-Hoeijmakers J. Presence of genetic variants among young men with severe COVID-19. JAMA. 2020; 324: 663-673. doi: 10.1001/jama.2020.13719

12. Rebl A, Goldammer T. Under control: The innate immunity of fish from the inhibitors’ perspective. Fish Shellfish Immunol. 2018; 77: 328-349. doi: 10.1016/j.fsi.2018.04.016

13. Mifsud EJ, Kuba M, Barr IG. Innate immune responses to influenza virus infections in the upper respiratory tract. Viruses. 2021; 13: 2009. doi: 10.3390/v13102090

14. Tsygan VN, Novik AA, Dulatova NKh, Zhogolev KD, Kozlov VK, Zubov NN. Chronic fatigue syndrome and immune dysfunction. Saint Petersburg: Izdatelstvo VMA; 2001. (In Russ.).

15. Artsimovich NG, Glushina TS. Chronic fatigue syndrome. Moscow: Nauchniy mir; 2002. (In Russ.).

16. Chen X, Shen Y, Wu M, Zhao J. IRF3 from mandarin fish thymus initiates interferon transcription. Fish Physiol Biochem. 2019; 45: 133-144. doi: 10.1007/s10695-018-0543-8

17. Pandey R, Dikhit MR, Kumar A, Dehury B, Pandey K, Topno RK, et al. Evaluating the immunomodulatory responses of LdODC-derived MHC Class-II restricted peptides against VL. Parazite Immunol. 2020; 42(4): e12699. doi: 10.1007/s10695-018-0543-8

18. Smirnov VS, Selivanov AA. Bioregulators in the prevention and treatment of influenza. Saint Petersburg: Nauka; 1996. (In Russ.).

19. Shuldyakov AA, Lyapina EP, Soboleva LA, Romantsov MG, Perminova TA, Kuznetsov VI, et al. The use of interferon inducers in an infectious disease clinic. Antibiotics and Chemotherapy. 2018; 63(3-4): 28-36. (In Russ.).

20. Leneva IA, Smirnov VS, Kudryavtseva TA, Fayzuloev EB, Gracheva AV, Kartashova NP, et al. Local antiviral activity of the drug «Thymogen®», nasal dosed spray, against SARS-CoV-2 coronavirus in vitro. Antibiotics and Chemotherapy. 2021; 66(5-6): 11-16. (In Russ.). doi: 10.37489/0235-2990-2021-66-5-6-11-16

21. Smirnov VS, Zarubaev VV, Petlenko SV. Biology of pathogens and control of influenza and acute respiratory viral infection. Saint Petersburg: Gippokrat; 2020. (In Russ.).

22. Rodionov AN, Khavinson VKh, Barbinov VV. Immunocorrective therapy for pyoderma caused by staphylococci multiresistant to antibiotics. Vestnik dermatologii i venerologii. 1990; 1: 42-45. (In Russ.).

23. Pinelis IS, Kuznik BI, Pinelis YuI. Features of bioregulatory therapy of dental diseases. The Transbaikalian Medical Bulletin. 2019; 1: 173-186. (In Russ.).